Interpretation of Report on Cardiovascular Health and Diseases in China 2022
Due to the acceleration of population aging and the prevalence of unhealthy lifestyles, the huge population with cardiovascular disease (CVD) risk factors, the burden of CVD continues to increase in China. CVD is still the leading cause of death among urban and rural residents in China. In 2020, CVD...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese General Practice Publishing House Co., Ltd
2023-11-01
|
| Series: | Zhongguo quanke yixue |
| Subjects: | |
| Online Access: | https://www.chinagp.net/fileup/1007-9572/PDF/20230408.pdf |
| _version_ | 1827289339988541440 |
|---|---|
| author | MA Liyuan, WANG Zengwu, FAN Jing, HU Shengshou |
| author_facet | MA Liyuan, WANG Zengwu, FAN Jing, HU Shengshou |
| author_sort | MA Liyuan, WANG Zengwu, FAN Jing, HU Shengshou |
| collection | DOAJ |
| description | Due to the acceleration of population aging and the prevalence of unhealthy lifestyles, the huge population with cardiovascular disease (CVD) risk factors, the burden of CVD continues to increase in China. CVD is still the leading cause of death among urban and rural residents in China. In 2020, CVD accounted for 48.00% and 45.86% of the causes of death in rural and urban areas, respectively, and two out of every five deaths were due to CVD. It is estimated that the number of current CVD patients in China is 330 million, including 13 million cases of stroke, 11.39 million cases of coronary heart disease, 8.9 million cases of heart failure, 5 million cases of pulmonary heart disease, 4.87 million cases of atrial fibrillation, 2.5 million cases of rheumatic heart disease, 2 million cases of congenital heart disease, 45.3 million cases of peripheral artery disease, and 245 million cases of hypertension. The total hospitalization costs were 270.901 billion yuan for CVD in China in 2020. The prevention and treatment of CVD in China still has a long way to go. In general, we should not only do a good job in secondary prevention and treatment of CVD, but also further strengthen the upstream treatment of modifiable risk factors such as hypertension, hyperglycemia and hyperlipidemia starting with both preventive treatment and treatment diseases. In addition, attention should be paid to the allocation and prioritization of health care and public health resources, so as to reach the inflection point of CVD prevention and treatment as early as possible. |
| first_indexed | 2024-04-24T11:47:56Z |
| format | Article |
| id | doaj.art-5553dd0ebc1d44f797d8a2b390760891 |
| institution | Directory Open Access Journal |
| issn | 1007-9572 |
| language | zho |
| last_indexed | 2024-04-24T11:47:56Z |
| publishDate | 2023-11-01 |
| publisher | Chinese General Practice Publishing House Co., Ltd |
| record_format | Article |
| series | Zhongguo quanke yixue |
| spelling | doaj.art-5553dd0ebc1d44f797d8a2b3907608912024-04-09T08:51:00ZzhoChinese General Practice Publishing House Co., LtdZhongguo quanke yixue1007-95722023-11-0126323975399410.12114/j.issn.1007-9572.2023.0408Interpretation of Report on Cardiovascular Health and Diseases in China 2022MA Liyuan, WANG Zengwu, FAN Jing, HU Shengshou0National Center for Cardiovascular Diseases/Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, ChinaDue to the acceleration of population aging and the prevalence of unhealthy lifestyles, the huge population with cardiovascular disease (CVD) risk factors, the burden of CVD continues to increase in China. CVD is still the leading cause of death among urban and rural residents in China. In 2020, CVD accounted for 48.00% and 45.86% of the causes of death in rural and urban areas, respectively, and two out of every five deaths were due to CVD. It is estimated that the number of current CVD patients in China is 330 million, including 13 million cases of stroke, 11.39 million cases of coronary heart disease, 8.9 million cases of heart failure, 5 million cases of pulmonary heart disease, 4.87 million cases of atrial fibrillation, 2.5 million cases of rheumatic heart disease, 2 million cases of congenital heart disease, 45.3 million cases of peripheral artery disease, and 245 million cases of hypertension. The total hospitalization costs were 270.901 billion yuan for CVD in China in 2020. The prevention and treatment of CVD in China still has a long way to go. In general, we should not only do a good job in secondary prevention and treatment of CVD, but also further strengthen the upstream treatment of modifiable risk factors such as hypertension, hyperglycemia and hyperlipidemia starting with both preventive treatment and treatment diseases. In addition, attention should be paid to the allocation and prioritization of health care and public health resources, so as to reach the inflection point of CVD prevention and treatment as early as possible.https://www.chinagp.net/fileup/1007-9572/PDF/20230408.pdfcardiovascular disease|epidemiology|health influencing factors|risk factors|prevalence|mortality|community-based prevention and control|rehabilitation|basic research|medical device development|fees, medical |
| spellingShingle | MA Liyuan, WANG Zengwu, FAN Jing, HU Shengshou Interpretation of Report on Cardiovascular Health and Diseases in China 2022 Zhongguo quanke yixue cardiovascular disease|epidemiology|health influencing factors|risk factors|prevalence|mortality|community-based prevention and control|rehabilitation|basic research|medical device development|fees, medical |
| title | Interpretation of Report on Cardiovascular Health and Diseases in China 2022 |
| title_full | Interpretation of Report on Cardiovascular Health and Diseases in China 2022 |
| title_fullStr | Interpretation of Report on Cardiovascular Health and Diseases in China 2022 |
| title_full_unstemmed | Interpretation of Report on Cardiovascular Health and Diseases in China 2022 |
| title_short | Interpretation of Report on Cardiovascular Health and Diseases in China 2022 |
| title_sort | interpretation of report on cardiovascular health and diseases in china 2022 |
| topic | cardiovascular disease|epidemiology|health influencing factors|risk factors|prevalence|mortality|community-based prevention and control|rehabilitation|basic research|medical device development|fees, medical |
| url | https://www.chinagp.net/fileup/1007-9572/PDF/20230408.pdf |
| work_keys_str_mv | AT maliyuanwangzengwufanjinghushengshou interpretationofreportoncardiovascularhealthanddiseasesinchina2022 |